← 홈

Antibody · EGFR

11개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 11개
AntibodystaleHuiKai LiPhase 2

Pucotenlimab (Pucotenlimab)

Biliary Tract Cancer (BTC); EGFR-positive Advanced Biliary Tract Carcinoma · Nasopharyngeal Cancinoma (NPC)

#NasopharyngealCancinomaNPC#Antibody#Phase2#항체#면역항체+4
임상시험 42상태 RECRUITING
AntibodystaleRoswell Park Cancer InstitutePhase 1

Nimotuzumab (Nimotuzumab)

EGFR Gene Mutation; Recurrent Non-Small Cell Lung Carcinoma · Advanced Cancer

#AdvancedCancer#Antibody#Phase1#항체#면역항체+4
임상시험 2상태 ACTIVE
AntibodystaleBenaroya Research InstitutePhase 2

Panitumumab or Cetuximab (Anti-EGFR, Anti-EGFR (Panitumumab or Cetuximab))

Colorectal Cancer; Cholangiocarcinoma · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleXinqiao Hospital of ChongqingPhase 2

Benmelstobart combined with Bevacizumab and chemotherapy (Benmelstobart combined with Bevacizumab and chemotherapy)

NSCLC Stage IV Without EGFR/ALK Mutation · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleCentre Francois BaclessePhase 2

atezolizumab (Tecentriq, Carboplatin + Pemetrexed + Atezolizumab)

NSCLC Stage IIIB; NSCLC Stage IV · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
효능 ORR 64.6%임상시험 1상태 ACTIVE
AntibodystaleCentre Francois BaclessePhase 2

atezolizumab (Tecentriq, Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab)

NSCLC Stage IIIB; NSCLC Stage IV · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
효능 ORR 42.9%임상시험 1상태 ACTIVE
AntibodystaleNational Cancer Center, KoreaPhase 2

Erlotinib plus Bevacizumab (Erlotinib plus Bevacizumab)

EGFR Positive Non-small Cell Lung Cancer · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleBeiGenePhase 2

Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

Non-squamous Non-small Cell Lung Cancer; EGFR Gene Mutation · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleWest China HospitalPhase 2

Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors (Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors)

Cancer of Biliary Duct · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleAmgenPhase 2

EGFR inhibitors (panitumumab, panitumumab (EGFR inhibitors))

Recurrence Free Survival · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3
효능 ORR 19%임상시험 1상태 RECRUITING
AntibodystaleShanghai Cancer Hospital, ChinaPhase 2

durvalumab (Imfinzi, pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT)

Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE